FluidForm, founded with the mission to revolutionize medicine, specializes in 3D bioprinting technology. The company focuses on additive manufacturing to create living human tissues, aiming to transform disease treatment through its patented FRESH™ technology. This innovative platform enables the bioprinting of silicone and living tissues that incorporate cells and vasculature, targeting advanced cell therapy and chronic disease cures.
Notable figures affiliated with FluidForm include leading experts in bioengineering and regenerative medicine. The company has attracted significant interest from investors in the biotech sector. Key achievements include the successful development and application of their FRESH™ technology, positioning FluidForm as a pioneer in the bioprinting industry. Their impact is evident in the potential to revolutionize treatments for chronic diseases, offering new hope for advanced medical therapies.
